Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 575 Show results per page	View Search Criteria \| Help With Results

	Title				Phase				Protocol IDs

	PharmacoEconomic Assessment IRESSA® in the Treatment of Non–Small-Cell Lung Cancer (NSCLC)				Phase IV				9461700718 NCT00173524
	Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)				Phase IV				D7913C00046 NCT00536107
	Pharmacokinetic Study on the Addition of Aprepitant to Cisplatin - Etoposide Treatment in Lung Cancer Patients				Phase IV				UMCN-AKF 07.02 EudraCTnr 2007-003347-73, NCT00588835
	Concurrent Chemoradiotherapy (CCRT) With Paclitaxel Plus Cisplatin in LA Non-Small-Cell Lung Cancer (NSCLC)				Phase IV				97-02-12 NCT00686322
	A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.				Phase IV				BO21015 2008-000662-23, NCT00700180
	Paclitaxel Plus Carboplatin With Endostar in Patients of Advanced Non-Small Cell Lung Cancer				Phase IV				XYL014 NCT00708812
	Efficacy and Safety Study of ZOMETA® in Treatment of High-Level NTX Non Small Cell Lung Cancer With Bone Metastasis				Phase IV				CZOL446ECN06T NCT00762346
	Screening Non Small Cell Lung Cancer With Bone Metastasis and Efficacy and Safety Research of Receiving Bisphosphonates				Phase IV				CZOL446ECN07 NCT00765687
	Safety and Efficacy Study of Gefitinib In Patients With Non-Small Cell Lung Cancer(NSCLC) Without Tumor Progression After First-Line Platinum-Based Chemotherapy				Phase IV				D7913L00071 NCT00769639
	Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)				Phase IV				D7913L00071 NCT00770588


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute